Streetbeat News

Products Services

ASNS

Actelis Networks, Inc. has received an order from a German energy provider for its encrypted, cyber-hardened, hybrid-fiber networking technology. This technology is designed to enhance the security and reliability of the energy provider's communications infrastructure.

Portfolio Pulse from Benzinga Newsdesk

November 29, 2023 | 1:33 pm

PENN

PENN Entertainment has entered into a partnership with the National Hockey League (NHL) to make its online sports betting brands, ESPN BET and theScore Bet, the official sports betting partners of the NHL. This collaboration is expected to enhance PENN's visibility and customer engagement by associating with the NHL's brand and fan base.

Portfolio Pulse from Benzinga Newsdesk

November 29, 2023 | 1:32 pm

MGRX

Mangoceuticals has chosen TRYBE Labs to be its provider for nationwide blood collection and testing services. This partnership could potentially enhance Mangoceuticals' operational efficiency and expand its service capabilities across the country.

Portfolio Pulse from Benzinga Newsdesk

November 29, 2023 | 1:32 pm

WKHS

Workhorse Group has expanded its dealer network to eight partners across the United States, aiming to enhance its distribution and service capabilities for customers. This expansion is part of the company's strategy to increase its market presence and improve customer service.

Portfolio Pulse from Benzinga Newsdesk

November 29, 2023 | 1:32 pm

GM

GM's CFO reported that the recent strike resulted in a production loss of 95,000 units, primarily affecting mid-size trucks and large crossovers. Additionally, GM's CEO anticipates that industry sales of electric vehicles (EVs) in the U.S. will exceed 1 million units for the first time this year.

Portfolio Pulse from Benzinga Newsdesk

November 29, 2023 | 1:31 pm

DIS

HON

MA

SNOW

Snowflake Inc (NYSE:SNOW) is set to report Q3 earnings with an expected EPS of 16 cents and revenue of $713.42 million. Analysts are focusing on cloud optimization challenges and potential AI benefits from new products like Snowflake Cortex. The stock is trading at a high P/E ratio of 246, posing downside risks if growth doesn't stabilize. Analyst ratings are generally positive, with a consensus price target of $183.27, while Morgan Stanley has a higher target of $215. Shares were up 0.73% at $171.55 recently.

Portfolio Pulse from Surbhi Jain

November 29, 2023 | 1:31 pm

BMY

GILD

JNJ

NVS

TSVT

The FDA is reviewing the risks of T-cell malignancies in patients treated with approved CAR T-cell therapies. Six therapies are affected, including products from Bristol Myers Squibb (BMY), 2seventy Bio (TSVT), Johnson & Johnson (JNJ), Novartis (NVS), and Gilead Sciences (GILD). The FDA acknowledges the benefits of these therapies outweigh the risks for approved uses. Bristol Myers Squibb and 2seventy Bio recently faced a delay in seeking expanded approval for Abecma. Analysts suggest varying levels of concern for different therapies, with Novartis' Kymriah potentially facing higher concerns.

Portfolio Pulse from Vandana Singh

November 29, 2023 | 1:30 pm

SOPA

Society Pass Incorporated (SoPa) (NASDAQ:SOPA), through its online travel platform NusaTrip, has announced a strategic partnership with Vietnam-based VNTravel Group. This collaboration will allow NusaTrip to offer regional and international flights and hotels to VNTravel's customers in Vietnam. VNTravel, a leading travel technology company, provides access to over 30,000 premium accommodations and partners with more than 200 global airlines. The partnership aims to capitalize on Vietnam's strong post-pandemic tourism recovery and the expected growth in digital sales. It will enable NusaTrip to expand its footprint in Southeast Asia and improve the booking experience for Vietnamese customers.

Portfolio Pulse from Benzinga Newsdesk

November 29, 2023 | 1:19 pm

PCSA

Processa Pharmaceuticals, Inc. (PCSA) CEO George Ng issued a shareholder letter detailing the company's pivot to oncology drug development, focusing on Next Generation Chemotherapy (NGC) agents to improve safety and efficacy for cancer patients. The letter outlines the current pipeline, including NGC-Capecitabine (PCS6422), NGC-Gemcitabine (PCS3117), and NGC-Irinotecan (PCS11T), all targeting various cancers. Processa aims to address chemotherapy's limitations and expand its market, leveraging a strong team and regulatory science approach. The company has a stable financial position with $6.9 million in cash as of September 30, 2023, and plans to out-license non-NGC assets to supplement funding. Upcoming milestones include completing Phase 1b study enrollment for NGC-Cap by early 2024 and meeting with the FDA to discuss Phase 2 study designs.

Portfolio Pulse from Benzinga Newsdesk

November 29, 2023 | 1:18 pm

PBLA

Panbela Therapeutics announced that the Data Safety Monitoring Board (DSMB) has recommended the continuation of its ASPIRE registration clinical trial without any modifications. This decision follows the second independent safety review of the trial, which is a positive development for the company's ongoing research.

Portfolio Pulse from Benzinga Newsdesk

November 29, 2023 | 1:16 pm